Clinical Trials


MAA-202 is a phase 1/2 open-label study designed to evaluate the PK / PD of MarzAA in FVII deficiency, Glanzmann Thrombasthenia, and in individuals on Hemlibra prophylaxis who experience breakthrough bleeding events. Subjects in the Phase 1 will receive an initial dose of intravenous (IV) MarzAA, followed by single dose SQ escalation and then multiple doses of SQ MarzAA. In the Phase 2 portion, subjects will receive up to 3 doses of SQ MarzAA to treat bleeding episodes. The primary endpoint will be hemostatic efficacy at 24 hours, the secondary endpoints include effective hemostasis at earlier timepoints, number of doses needed, requirement for rescue medication, and safety.